Mayne Pharma Group (HG6) AI Stock Analysis

Company Guidance

The company guided to a fiscally disciplined FY‑27 focused on growing women's health, scaling DistributeRx and improving margins: management expects women's‑health gross margins to improve year‑on‑year as NEXTSTELLIS coverage expands and ANNOVERA returns (a ~USD11m headwind in FY‑26) are addressed, and highlighted menopause tailwinds (≈75m U.S. women peri/post‑menopause, +1.3m/year; market seen rising ~60% to USD15–25bn by 2030) after the FDA removed the BIJUVA black‑box; product traction cited included BIJUVA net sales +20% to USD15m, IMVEXXY USD29.3m, NEXTSTELLIS USD45.2m and ANNOVERA USD25.7m. On DistributeRx, management signaled near‑term conversion of a “significant percentage” of seven manufacturers covering 13 products (will provide revenue detail at 1H FY‑27), noted ~5,000 new prescribers since launch, a current portfolio of 31 Mayne dermatology and 208 third‑party products, and a major Adelaide Apothecary expansion (up to 2.5m prescriptions p.a., ~USD4m capex) plus a new facility to enable a ~7x capacity increase across two phases. Corporate guidance included no further Cosette scheme costs, litigation expected at normal scale (no quantitative guidance), an expectation that one‑off costs will be lower year‑on‑year, and continued emphasis on channel optimization, profitable portfolio expansion and disciplined, capital‑efficient M&A.